ARTICLE | Management Tracks
Karen Massey succeeding Woods as argenx COO
Plus: BioCentury’s Bernstein joins C-Path board and updates from Marengo and Certara
March 3, 2023 12:58 AM UTC
Autoimmune disease company argenx S.E. (Euronext:ARGX; NASDAQ:ARGX) hired Karen Massey as COO, effective March 13. She succeeds Keith Woods, who will remain at the company for a transition period to support subcutaneous efgartigimod’s launch before retiring. Massey was SVP of product development and global clinical operations at Genentech Inc. company of Roche (SIX:ROG; OTCQX:RHHBY).
BioCentury Inc. co-founder and Chairman Karen Bernstein joined the board of the Critical Path Institute. Bernstein is a director at Ovid Therapeutics Inc. (NASDAQ:OVID) and Codiak BioSciences Inc. (NASDAQ:CDAK), and a member of the board of trustees of the Keck Graduate Institute and the board of overseers of Scripps Research...